Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2014-03-25 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec FY 2013: Execute on Innovate to create value
Earnings Release Classification · 100% confidence The document explicitly states it announces 'financial results for the fiscal year ended 31 December 2013' and provides detailed financial figures (Revenues, Operating result, EBITDA, Net loss) for FY 2013, along with guidance for 2014. This content is characteristic of an Annual Report or a comprehensive report covering the full fiscal year. Since the document is extensive (over 21,000 characters) and contains detailed financial statements and operational reviews, it is classified as the full Annual Report (10-K equivalent in content, though the filing might be an AR in reality, 10-K is the standard for full annual performance review). Given the context of a German company announcing 'FY 2013' results, the closest standard US equivalent for a full annual performance review is 10-K. If it were just a summary, ER or IR would apply, but the depth suggests the full report content. FY 2013
2014-03-25 English
Evotec AG, Geschäftsbericht 2013 Präsentation
Investor Presentation Classification · 98% confidence The document text contains slides with titles like "Highlights 2013", "Evotec 2014 – Update on Action Plan 2016", "Financial performance 2013", and "Outlook 2014". It details financial figures (€ 85.9 m revenues, EBITDA, liquidity) and strategic updates, including segment breakdowns (EVT Execute, EVT Innovate). This structure, focusing on past performance review and future guidance within a presentation format, strongly indicates an Investor Presentation (IP) or potentially a Management Discussion & Analysis (MDA) if it were a narrative report. Given the clear slide structure and presentation language ("Agenda", bullet points summarizing results and strategy), Investor Presentation (IP) is the most appropriate classification. It is not a formal regulatory filing like 10-K or ER, but rather a presentation used to communicate these results to investors.
2014-03-25 English
Annual Financial Statements 2013
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2013' and contains a comprehensive table of contents covering financial statements, management reports, auditor's reports, and corporate governance. It is a full-length annual report, not an announcement or a summary, and includes detailed financial data for the fiscal year 2013. FY 2013
2014-03-25 German
Evotec acquires Bionamics GmbH to accelerate 'EVT Innovate' strategy
M&A Activity Classification · 99% confidence The document is a press release dated March 24, 2014, announcing the acquisition of Bionamics GmbH by Evotec AG. It details the strategic rationale, key personnel changes related to the acquisition (appointment of Dr. Timm Jessen), and provides background information on both companies. This type of announcement, focusing on corporate transactions like mergers or acquisitions, aligns directly with the definition of M&A Activity (TAR). It is not a formal regulatory filing like a 10-K, an earnings release, or a proxy statement.
2014-03-24 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details notifications received according to Article 21, Section 1 of the WpHG (German Securities Trading Act) regarding changes in voting rights thresholds (exceeding 3%) held by Morgan Stanley entities in Evotec AG. This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions 'Publication according to § 26 paragraph. 1 WpHG', the core content is the voting rights change notification.
2014-03-21 English
Declaration of Compliance 2013
Governance Information Classification · 98% confidence The document is explicitly titled 'Declaration of Compliance with the German Corporate Governance Code for the year 2013'. It details the company's adherence (or exceptions to adherence) to the recommendations of the German Corporate Governance Code for the fiscal year 2013, signed off by the Management Board and Supervisory Board. This content directly relates to the company's internal rules, board structure, and governance practices, matching the definition for Governance Information (CGR). It is not an Annual Report (10-K), an Audit Report (AR), or a general Investor Presentation (IP).
2014-03-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.